These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 25131839)

  • 1. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial.
    Yang YS; Su YF; Yang HW; Lee YH; Chou JI; Ueng KC
    Phytother Res; 2014 Dec; 28(12):1770-7. PubMed ID: 25131839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels.
    Sahebkar A
    Clin Nutr; 2014 Jun; 33(3):406-14. PubMed ID: 24139527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials.
    Qin S; Huang L; Gong J; Shen S; Huang J; Ren H; Hu H
    Nutr J; 2017 Oct; 16(1):68. PubMed ID: 29020971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.
    Mohammadi A; Sahebkar A; Iranshahi M; Amini M; Khojasteh R; Ghayour-Mobarhan M; Ferns GA
    Phytother Res; 2013 Mar; 27(3):374-9. PubMed ID: 22610853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial.
    Panahi Y; Khalili N; Sahebi E; Namazi S; Reiner Ž; Majeed M; Sahebkar A
    Complement Ther Med; 2017 Aug; 33():1-5. PubMed ID: 28735818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of curcumin supplementation on high-sensitivity C-reactive protein, serum adiponectin, and lipid profile in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial.
    Adibian M; Hodaei H; Nikpayam O; Sohrab G; Hekmatdoost A; Hedayati M
    Phytother Res; 2019 May; 33(5):1374-1383. PubMed ID: 30864188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: a subanalysis of the Treating to New Targets (TNT) study.
    Deedwania PC; Shepherd J; Breazna A; DeMicco DA;
    Diabetes Obes Metab; 2016 Jan; 18(1):56-63. PubMed ID: 26434404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No Beneficial Effects of Resveratrol on the Metabolic Syndrome: A Randomized Placebo-Controlled Clinical Trial.
    Kjær TN; Ornstrup MJ; Poulsen MM; Stødkilde-Jørgensen H; Jessen N; Jørgensen JOL; Richelsen B; Pedersen SB
    J Clin Endocrinol Metab; 2017 May; 102(5):1642-1651. PubMed ID: 28182820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Effects of Cucumis sativus Seed Extract on Serum Lipids in Adult Hyperlipidemic Patients: A Randomized Double-Blind Placebo-Controlled Clinical Trial.
    Soltani R; Hashemi M; Farazmand A; Asghari G; Heshmat-Ghahdarijani K; Kharazmkia A; Ghanadian SM
    J Food Sci; 2017 Jan; 82(1):214-218. PubMed ID: 27886382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of body fat and improved lipid profile associated with daily consumption of a Puer tea extract in a hyperlipidemic population: a randomized placebo-controlled trial.
    Jensen GS; Beaman JL; He Y; Guo Z; Sun H
    Clin Interv Aging; 2016; 11():367-76. PubMed ID: 27069360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial.
    Maron DJ; Lu GP; Cai NS; Wu ZG; Li YH; Chen H; Zhu JQ; Jin XJ; Wouters BC; Zhao J
    Arch Intern Med; 2003 Jun; 163(12):1448-53. PubMed ID: 12824094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial.
    Panahi Y; Kianpour P; Mohtashami R; Jafari R; Simental-Mendía LE; Sahebkar A
    J Cardiovasc Pharmacol; 2016 Sep; 68(3):223-9. PubMed ID: 27124606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nut consumption and blood lipid levels: a pooled analysis of 25 intervention trials.
    Sabaté J; Oda K; Ros E
    Arch Intern Med; 2010 May; 170(9):821-7. PubMed ID: 20458092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus.
    Gutierrez MJ; Rosenberg NL; Macdougall DE; Hanselman JC; Margulies JR; Strange P; Milad MA; McBride SJ; Newton RS
    Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):676-83. PubMed ID: 24385236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial.
    Panahi Y; Khalili N; Hosseini MS; Abbasinazari M; Sahebkar A
    Complement Ther Med; 2014 Oct; 22(5):851-7. PubMed ID: 25440375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of low molecular weight procyanidin rich extract from french maritime pine bark on cardiovascular disease risk factors in stage-1 hypertensive subjects: Randomized, double-blind, crossover, placebo-controlled intervention trial.
    Valls RM; Llauradó E; Fernández-Castillejo S; Puiggrós F; Solà R; Arola L; Pedret A
    Phytomedicine; 2016 Nov; 23(12):1451-1461. PubMed ID: 27765365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.
    Santos JR; Saumoy M; Curran A; Bravo I; Llibre JM; Navarro J; Estany C; Podzamczer D; Ribera E; Negredo E; Clotet B; Paredes R;
    Clin Infect Dis; 2015 Aug; 61(3):403-8. PubMed ID: 25870325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.